XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2
License and Agreements (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Aug. 12, 2020
May 31, 2020
Jan. 31, 2020
Jan. 31, 2019
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Nov. 24, 2019
Mar. 31, 2018
License and Agreements (Details) [Line Items]                      
Assignment fee                     $ 100,000
Milestone payment                   $ 50,000  
Accounts payable due         $ 123,000   $ 123,000   $ 21,000    
Recorded research and development costs         5,110,805 $ 2,762,170 10,372,409 $ 8,040,422      
Pre-marketing approvals $ 25,000,000                    
Interest fee             500,000        
Research and development expenses         36,393 449,846 184,273 487,946      
Other receivable         1,812,975   1,812,975   1,628,703    
Master Services Agreement [Member]                      
License and Agreements (Details) [Line Items]                      
Agreement term, description       In January 2019, the Company cancelled all of the individual study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba Strategy Point Innovations (“SPI”)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical research and development services in order to take advantage of eligible Canadian Tax Credits.              
Accounts payable due         303,000   303,000   0    
Recorded research and development costs         732,000   2,317,000        
Clinical Network Services Pty Ltd. [Member]                      
License and Agreements (Details) [Line Items]                      
Agreement description     to provide initial contract clinical research and development services for the Company’s drug product candidates. The accounts payable due in connection with this agreement was approximately AUD$43,000 (US$30,000) and AUD$138,000 (US$100,000) as of June 30, 2022 and December 31, 2021, respectively. During the three and six months ended June 30, 2022, the Company recorded research and development costs of approximately AUD$115,000 (US$82,000) and AUD$463,000 (US$333,000), respectively, pertaining to this agreement. During the three and six months ended June 30, 2021, the Company recorded research and development costs of approximately AUD$216,000 (US$166,000) and AUD$921,000 (US$710,000), respectively, pertaining to this agreement                
Clinical trial research agreement with Nucleus Network Pty Ltd. [Member]                      
License and Agreements (Details) [Line Items]                      
Agreement description   to provide a Phase I study of one of the Company’s drug candidates, Tacrolimus. The accounts payable due in connection with this agreement was approximately $0 and AUD$161,000 (US$117,000) as of June 30, 2022 and December 31, 2021, respectively. During the three and six months ended June 30, 2022, the Company did not record any research and development costs pertaining to this agreement. During the three and six months ended June 30, 2021, the Company recorded research and development costs of approximately AUD$202,000 (US$156,000) and AUD$446,000 (US$344,000), respectively, pertaining to this agreement.                  
Contract Manufacturing Services [Member] | Master Services Agreement [Member]                      
License and Agreements (Details) [Line Items]                      
Accounts payable due         1,034,000   1,034,000        
Recorded research and development costs           512,000   2,380,000      
April 2019 [Member]                      
License and Agreements (Details) [Line Items]                      
Recorded research and development costs         180,000 303,000 626,000 797,000      
January 2021 [Member]                      
License and Agreements (Details) [Line Items]                      
Recorded research and development costs         262,000 $ 105,000 580,000 $ 301,000      
January 2021 [Member] | Master Services Agreement [Member]                      
License and Agreements (Details) [Line Items]                      
Accounts payable due         243,000   243,000   $ 313,000    
January 2022 [Member]                      
License and Agreements (Details) [Line Items]                      
Recorded research and development costs         $ 1,073,000   $ 1,299,000